Abstract 15P
Background
Although electrocautery is popularly used for the skin flap preparations at the time of mastectomy, we have been making the skin flap using the tumescent technique for the protects of the wound and skin flap since 2012 in our department. The aim of the study is to examine the differences of the clinical outcomes by between the surgeons (specialist who is familiar with breast surgery vs non-special surgeons).
Methods
166 patients who underwent the reconstruction after 1ststage of mastectomy with the tumescent technique at our hospital from March 2012 to December 2018 were enrolled. Tumescent technique; just before skin incision, we injected the tumescent solusions (200ml of physiological saline, 1mg of adrenaline, 20ml of xylocaine) subcutaneously into the breast and we started the sharp skin incision containing the tumor and around the areola like the spindle shape. If the tumor is close to the skin, we resected the skin just above tumor. We separated between subcutaneous and mammary tissue, and made the skin flap widely using the mechenbaum scissor and the wound retractor for protect the skin cutting edge. The most important things of this technique are to get the viewing field using the wound retractor with light and and the hemostasis exactly using McCannd forceps.
Results
patients characteristics is mean age 47.9 years (25-73 years), BMI is mean 21.1 (16.4-35.4), complication disease are 4 cases of hypertension, 4 cases of diabetes mellitus, 3 cases of radiotherapy previously, we performed surgery for 52 cases of DICS, for 114 cases of the invasive cancer including 10 cases of the axillary lymph node dissections, specialist performed 100 cases of mastectomy, on the other hand non-special surgeons performed 66 cases of mastectomy. Mean operation time is 56 min and 62 min (p = 0.314), there are no significant differences between the weight of the resected tissue and operation time (p = 0.062. Mean blood loss is 54ml each. 49 case (29%) of the mild necrosis of the skin, and 8 cases (4.7%) of hematoma were totally occurred after surgery, There are also no significant differences between specialist and non-special surgeons.
Conclusions
Mastectomy using the tumescent technique is easy and safe for not only specialist but also non-special surgeons.
Clinical trial identification
Editorial acknowledgement
Tissue expander and Inplants were approved for clinical use in Japan in July 2013.Since 2013, the reconstruction after mastectomy has been increasing year by year in Japan.
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
221P - Comparative analysis of first-line immune checkpoint inhibitor versus carboplatin-based chemotherapy for cisplatin-ineligible metastatic urothelial carcinoma: A multicenter, retrospective real-world evidence
Presenter: Hsiang‐Lan Lai
Session: Poster display session
Resources:
Abstract
222P - Does tumor grade really improve the prognostic ability of the staging system for men with penile cancer: A SEER database analysis
Presenter: Ravi Kanodia
Session: Poster display session
Resources:
Abstract
223TiP - EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma
Presenter: Daniel Petrylak
Session: Poster display session
Resources:
Abstract
230P - Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort
Presenter: Lingying Wu
Session: Poster display session
Resources:
Abstract
231P - Cost-effectiveness of olaparib vs routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore
Presenter: David SP Tan
Session: Poster display session
Resources:
Abstract
233P - Incorporation of correlative studies in ovarian cancers in the era of precision medicine: Assessment of accountability and utility
Presenter: Nadia Hitchen
Session: Poster display session
Resources:
Abstract
234P - Implementation of mainstream BRCA testing in epithelial ovarian cancer in a tertiary centre
Presenter: Edbert Wong
Session: Poster display session
Resources:
Abstract
235P - The efficacy of radiation therapy in ovarian carcinoma: A propensity score analysis of a population-based study
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
236P - Front-line maintenance therapy for platinum-sensitive ovarian cancer: What’s next PARP inhibitors?
Presenter: Han Gong
Session: Poster display session
Resources:
Abstract
237P - PARP inhibitor in platinum resistant ovarian cancer: Single center real world experience
Presenter: Saphalta Baghmar
Session: Poster display session
Resources:
Abstract